Vantaris Surgical Secures $30M in Series A Funding for Kidney Stone Treatment System

Ventaris Surgical just dropped a clean $30M Series A, and anyone who understands kidney stone procedures knows why this matters. Stones get fragmented, fragments get left behind, and patients end up starring in a sequel nobody wanted. This round is about finishing the job, not celebrating partial wins. Longitude Capital led it with conviction, Vensana Capital stepped in with serious intent, and Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners stayed involved because progress like this is earned in the OR, not manufactured in slides.

Ventaris Surgical was formed in April 2024 by people who already learned the hard lessons. Surag Mantri, Founder and CEO, spent more than a decade at PROCEPT BioRobotics turning complex urology tech into real clinical tools, stacking patents and credibility along the way. Matthew Sprinkel, Co-Founder, ran across product, marketing, and sales at PROCEPT, which means this company speaks fluently in surgeon, hospital, and buyer. 18 months after founding, Ventaris treated its first patient in November 2025. That timeline is not luck. That is muscle memory.

Kidney stone surgery is one of the most common urologic procedures on the planet, yet the industry has quietly accepted inefficiency for years. Residual fragments show up again, recurrence rates stay stubborn, and surgeons carry the fatigue of tools that demand more effort than they should. Ventaris is building a next-generation ureteroscopic system designed to reduce friction in the procedure so surgeons can focus on complete stone clearance. Fewer fragments means fewer repeat interventions, fewer ER visits, and fewer conversations that start with "we need to go back in."

The market is already massive and still growing, but scale alone does not fix outcomes. What changes the equation is technology that respects anatomy, workflow, and human endurance. That is why this board matters. Varun Gupta of Longitude Capital and Justin Klein of Vensana Capital join Amir Abolfathi, whose track record across Align Technology, EndoTex Interventional Systems, and Tusker Medical speaks louder than any tagline. This is experience where it counts, aligned around execution, not noise.

The $30M Series A is fuel for clinical development, regulatory progress, and commercial readiness, all anchored in San Carlos where Ventaris has its HQ and manufacturing in place. This is not hype chasing attention. It is steady pressure applied with precision, the kind surgeons appreciate and patients never see, except in the form of better outcomes and fewer return visits. Sometimes progress is not loud. It is thorough, deliberate, and finished properly the first time.